Visionary Wealth Advisors Makes New $407,000 Investment in Halozyme Therapeutics, Inc. $HALO

Visionary Wealth Advisors bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the second quarter, HoldingsChannel reports. The institutional investor bought 5,195 shares of the biopharmaceutical company’s stock, valued at approximately $407,000.

Several other hedge funds have also made changes to their positions in the company. Whalen Wealth Management Inc. bought a new position in shares of Halozyme Therapeutics during the 2nd quarter worth $602,000. Infrastructure Capital Advisors LLC purchased a new position in shares of Halozyme Therapeutics during the second quarter valued at $673,000. Cibc World Market Inc. bought a new stake in shares of Halozyme Therapeutics in the second quarter valued at about $309,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Halozyme Therapeutics in the second quarter valued at about $3,756,000. Finally, Sanctuary Advisors LLC purchased a new stake in Halozyme Therapeutics in the second quarter worth about $1,535,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Halozyme Therapeutics

In other news, Director Mahesh Krishnan sold 7,304 shares of the company’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the transaction, the director directly owned 14,462 shares of the company’s stock, valued at approximately $1,084,650. This represents a 33.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total value of $2,083,600.00. Following the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $79,987,320.40. This represents a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 64,103 shares of company stock valued at $5,226,496 over the last 90 days. Insiders own 2.50% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on HALO. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. Leerink Partners upgraded shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $83.00 to $110.00 in a research note on Friday, August 7th. Wells Fargo & Company increased their price objective on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Finally, TD Cowen boosted their price objective on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Nine analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $91.20.

Halozyme Therapeutics Price Performance

Shares of HALO stock opened at $108.64 on Tuesday. The stock’s 50-day moving average is $83.94 and its 200 day moving average is $73.96. Halozyme Therapeutics, Inc. has a 1-year low of $61.22 and a 1-year high of $109.10. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. The company has a market cap of $12.33 billion, a P/E ratio of 32.43, a PEG ratio of 0.43 and a beta of 0.85.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. The business had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The firm’s revenue was up 47.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Research analysts predict that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.